AHA/ASA guideline recommendations for secondary prevention of stroke

Ischemic Stroke Microchapters
Main Stroke Page
Transient ischemic attack
Hemorrhagic Stroke Page
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Stroke from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Echocardiography
Ultrasound
Other Imaging Findings
Treatment
Early Assessment
Medical Therapy
Surgery
Rehabilitation
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
AHA/ASA Guidelines for Stroke
Case Studies
Case #1
AHA/ASA guideline recommendations for secondary prevention of stroke On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for secondary prevention of stroke All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on AHA/ASA guideline recommendations for secondary prevention of stroke
CDC on AHA/ASA guideline recommendations for secondary prevention of stroke
AHA/ASA guideline recommendations for secondary prevention of stroke in the news
Blogs on AHA/ASA guideline recommendations for secondary prevention of stroke
Directions to Hospitals Treating Stroke
Risk calculators and risk factors for AHA/ASA guideline recommendations for secondary prevention of stroke

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]

2014 AHA/ASA Guidelines for the Secondary Prevention of Stroke

Hypertension

Class I

"1. (Level of Evidence: A)"

"2. (Level of Evidence: A)"

"3. (Level of Evidence: A)"

Class IIb

"1. Niacin may be considered for patients with low HDL cholesterol or elevated Lp(a), but its efficacy in pre- venting ischemic stroke in patients with these conditions is not established. Caution should be used with niacin because it increases the risk of myopathy (Level of Evidence: B)"

"2. Fibric acid derivatives may be considered for patients with hypertriglyceridemia, but their efficacy in pre- venting ischemic stroke is not established(Level of Evidence: C)"

"3. Treatment with nonstatin lipid-lowering therapies such as fibric acid derivatives, bile acid sequestrants, niacin, and ezetimibe may be considered in patients who cannot tolerate statins, but their efficacy in preventing stroke is not established (Level of Evidence: C)"

Class IIb

"1. (Level of Evidence: B)"

"2. (Level of Evidence: C)"